The American Journal of Medicine
Volume 121, Issue 11 , Pages 1002-1007.e1 , November 2008

Prior Statin Use Is Associated with Improved Outcomes in Community-acquired Pneumonia

  • James D. Chalmers, MBChB, MRCP (UK)

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to James Chalmers, MBChB, MRCP (UK), Department of Respiratory Medicine, 51 Old Dalkeith Road, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, United Kingdom
    • ,
  • Aran Singanayagam, MBChB, MRCP (UK)
    • ,
  • Maeve P. Murray, MBChB, MRCP (UK)
    • ,
  • Adam T. Hill, MD

References 

  1. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am J Med. 1985;78:32S–37S
  2. Van de Garde EM, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax. 2006;61(11):957–961
  3. Schlienger RG, Fedson DS, Jick SS, et al. Statins and the risk of pneumonia: a population-based, nested case control study. Pharmacotherapy. 2007;27(3):325–332
  4. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;6:82
  5. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103(15):1933–1935
  6. Musial J, Undas A, Gajewski P, et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77(2-3):247–253
  7. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet. 1999;353:118–119
  8. Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxy-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med. 2005;171:606–615
  9. Admirall J, Bolibar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125(4):1192–1195
  10. Fernandez-Serrano S, Dorca J, Coromines M, et al. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol. 2003;10(5):813–820
  11. Glynn P, Coakley R, Kilgallen I. Circulating interleukin 6 and interleukin 10 in community-acquired pneumonia. Thorax. 1999;54(1):51–55
  12. Puren J, Feldman C, Savage N, et al. Patterns of cytokine expression in community-acquired pneumonia. Chest. 1995;107:1342–1349
  13. Majumdar SR, McAllister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community-acquired pneumonia: population based prospective cohort study. BMJ. 2006;333:999
  14. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of prior outpatient ACE inhibitor use on 30-day mortality in patients hospitalized with community-acquired pneumonia. BMC Pulm Med. 2005;5:12
  15. Lim WS, van der Eerden MM, Laing R, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382
  16. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250
  17. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic Effusions. Am J Med. 1980;69:507–512l
  18. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzme A reductase inhibitor, improves endothelium function within one month. Circulation. 1997;95:1126–1131
  19. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:556–562
  20. Rosenson R, Tangney C, Casey L. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353:983–984
  21. Castell JV, Gomez-LEchon MJ, David M, et al. Acute phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–1186
  22. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110:880–885
  23. Kruger P, Fitzsimmons K, Cook D, et al. Statin therapy is associated with fewer deaths in patients with bacteremia. Intensive Care Med. 2006;32:75–79
  24. Chalmers J, Singanayagam A, Hill A. C-reactive protein is an independent marker of severity in community-acquired pneumonia. Am J Med. 2008;121(3):219–225
  25. Hansson LO, Hedlund JU, Ortqvist A. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scand J Clin Lab Invest. 1997;57:111–118
  26. Lane SM, Maender KC, Awender NE, Maron MB. Adrenal epinephrine increases alveolar liquid clearance in a canine model of neurogenic pulmonary edema. Am J Respir Crit Care Med. 1998;158:760–768
  27. Pittet JF, Wiener-Kronish JP, McElroy MC, et al. Stimulation of lung epithelial liquid clearance by endogenous release of catecholamines in septic shock in anesthetized rats. J Clin Invest. 1994;94:663–671
  28. Su X, Robriquet L, Folkesson HG, Metthay MA. Protective effect of endogenous beta-adrenergic tone on lung fluid balance in acute bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol. 2006;290(4):L769–L776

PII: S0002-9343(08)00704-3

doi: 10.1016/j.amjmed.2008.06.030

The American Journal of Medicine
Volume 121, Issue 11 , Pages 1002-1007.e1 , November 2008

Article Tools

* Image Usage & Resolution